The present invention relates to humanised antibodies that bind phosphatase of regenerating liver-3 (PRL3) and use of said antibodies for the treatment of cancer. Also claimed is an in vitro method of determining the cellular localisation of PRL3 in a cell, wherein expression of PRL3 at the cell surface indicates that the cell is cancerous.